Sumitomo Pharma Co Ltd (OTCPK:DNPUF)
$ 2.26 0 (0%) Market Cap: 771.97 Mil Enterprise Value: 3.21 Bil PE Ratio: 0 PB Ratio: 0.78 GF Score: 56/100

Q1 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript

Jul 29, 2019 / 07:45AM GMT
Release Date Price: $17.25 (-11.54%)
Hisayoshi Kashima
Sumitomo Dainippon Pharma Co., Ltd. - Senior Director & Corporate Controller

[Interpreted] I'm Kashima, presenting the financial results for the first quarter fiscal year 2019 and the clinical development updates. Please look at Slide 3.

I would like to present the financial results for the first quarter based on IFRS core basis. Total revenue was JPY 117.5 billion, slightly up by JPY 1.6 billion year-on-year. Revenue grew in North America and China, but dropped in Japan.

Sales expenses declined mainly in North America, and R&D expenses decreased as well. As a result, core operating profit increased by JPY 3.9 billion year-on-year to JPY 22.3 billion.

Changes in fair value of contingent consideration was up by JPY 21 billion year-on-year, driven by favorable expenses due to the discontinuation of Phase III study of napabucasin for patients with pancreatic cancer. The operating profit as a result improved significantly from a year earlier to JPY 40.4 billion.

On the other hand, net profit attributable to owners of the parent fell sharply,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot